177 related articles for article (PubMed ID: 16507561)
1. In vitro acanthamoebicidal activity of a killer monoclonal antibody and a synthetic peptide.
Fiori PL; Mattana A; Dessì D; Conti S; Magliani W; Polonelli L
J Antimicrob Chemother; 2006 May; 57(5):891-8. PubMed ID: 16507561
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of a monoclonal killer anti-idiotypic antibody and a synthetic killer peptide against oral isolates of Candida spp. differently susceptible to conventional antifungals.
Manfredi M; McCullough MJ; Conti S; Polonelli L; Vescovi P; Al-Karaawi ZM; Porter SR
Oral Microbiol Immunol; 2005 Aug; 20(4):226-32. PubMed ID: 15943767
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis.
Polonelli L; Magliani W; Conti S; Bracci L; Lozzi L; Neri P; Adriani D; De Bernardis F; Cassone A
Infect Immun; 2003 Nov; 71(11):6205-12. PubMed ID: 14573638
[TBL] [Abstract][Full Text] [Related]
4. From Pichia anomala killer toxin through killer antibodies to killer peptides for a comprehensive anti-infective strategy.
Polonelli L; Magliani W; Ciociola T; Giovati L; Conti S
Antonie Van Leeuwenhoek; 2011 Jan; 99(1):35-41. PubMed ID: 20714805
[TBL] [Abstract][Full Text] [Related]
5. A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication.
Casoli C; Pilotti E; Perno CF; Balestra E; Polverini E; Cassone A; Conti S; Magliani W; Polonelli L
AIDS; 2006 Apr; 20(7):975-80. PubMed ID: 16603848
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis.
Travassos LR; Silva LS; Rodrigues EG; Conti S; Salati A; Magliani W; Polonelli L
J Antimicrob Chemother; 2004 Nov; 54(5):956-8. PubMed ID: 15448128
[TBL] [Abstract][Full Text] [Related]
7. A synthetic peptide as a novel anticryptococcal agent.
Cenci E; Bistoni F; Mencacci A; Perito S; Magliani W; Conti S; Polonelli L; Vecchiarelli A
Cell Microbiol; 2004 Oct; 6(10):953-61. PubMed ID: 15339270
[TBL] [Abstract][Full Text] [Related]
8. From yeast killer toxins to antibiobodies and beyond.
Magliani W; Conti S; Travassos LR; Polonelli L
FEMS Microbiol Lett; 2008 Nov; 288(1):1-8. PubMed ID: 18785931
[TBL] [Abstract][Full Text] [Related]
9. In vitro candidacidal activity of a synthetic killer decapeptide (KP) against Candida albicans cells adhered to resin acrylic discs.
Manfredi M; Merigo E; Salati A; Conti S; Savi A; Polonelli L; Bonanini M; Vescovi P
J Oral Pathol Med; 2007 Sep; 36(8):468-71. PubMed ID: 17686004
[TBL] [Abstract][Full Text] [Related]
10. Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide.
Cenci E; Pericolini E; Mencacci A; Conti S; Magliani W; Bistoni F; Polonelli L; Vecchiarelli A
J Leukoc Biol; 2006 Jan; 79(1):40-5. PubMed ID: 16244115
[TBL] [Abstract][Full Text] [Related]
11. In vitro amoebicidal activity of Origanum syriacum and Origanum laevigatum on Acanthamoeba castellanii cysts and trophozoites.
Degerli S; Tepe B; Celiksoz A; Berk S; Malatyali E
Exp Parasitol; 2012 May; 131(1):20-4. PubMed ID: 22417972
[TBL] [Abstract][Full Text] [Related]
12. Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy.
Magliani W; Conti S; Salati A; Arseni S; Ravanetti L; Frazzi R; Polonelli L
Curr Med Chem; 2004 Jul; 11(13):1793-800. PubMed ID: 15279582
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection.
Conti G; Magliani W; Conti S; Nencioni L; Sgarbanti R; Palamara AT; Polonelli L
Antimicrob Agents Chemother; 2008 Dec; 52(12):4331-7. PubMed ID: 18824612
[TBL] [Abstract][Full Text] [Related]
14. In vitro amoebicidal activity of propolis on Acanthamoeba castellanii.
Topalkara A; Vural A; Polat Z; Toker MI; Arici MK; Ozan F; Cetin A
J Ocul Pharmacol Ther; 2007 Feb; 23(1):40-5. PubMed ID: 17341149
[TBL] [Abstract][Full Text] [Related]
15. Contact lens solution efficacy against Acanthamoeba castellani.
Mowrey-McKee M; George M
Eye Contact Lens; 2007 Sep; 33(5):211-5. PubMed ID: 17873623
[TBL] [Abstract][Full Text] [Related]
16. In vitro amoebicidal activity of a ceragenin, cationic steroid antibiotic-13, against Acanthamoeba castellanii and its cytotoxic potential.
Polat ZA; Savage PB; Genberg C
J Ocul Pharmacol Ther; 2011 Feb; 27(1):1-5. PubMed ID: 21142940
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity.
Magliani W; Conti S; de Bernardis F; Gerloni M; Bertolotti D; Mozzoni P; Cassone A; Polonelli L
Nat Biotechnol; 1997 Feb; 15(2):155-8. PubMed ID: 9035141
[TBL] [Abstract][Full Text] [Related]
18. Killer peptide: a novel paradigm of antimicrobial, antiviral and immunomodulatory auto-delivering drugs.
Magliani W; Conti S; Ciociola T; Giovati L; Zanello PP; Pertinhez T; Spisni A; Polonelli L
Future Med Chem; 2011 Jul; 3(9):1209-31. PubMed ID: 21806382
[TBL] [Abstract][Full Text] [Related]
19. Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies.
Conti S; Fanti F; Magliani W; Gerloni M; Bertolotti D; Salati A; Cassone A; Polonelli L
J Infect Dis; 1998 Mar; 177(3):807-11. PubMed ID: 9498471
[TBL] [Abstract][Full Text] [Related]
20. Peptide derived from anti-idiotypic single-chain antibody is a potent antifungal agent compared to its parent fungicide HM-1 killer toxin peptide.
Kabir ME; Karim N; Krishnaswamy S; Selvakumar D; Miyamoto M; Furuichi Y; Komiyama T
Appl Microbiol Biotechnol; 2011 Dec; 92(6):1151-60. PubMed ID: 21691785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
